Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document ianalumab - BAFF-R inhibitor Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic > Immunology Neuroscience Oncology Other Global Health Abbreviations References NCT05349214 NEPTUNUS-2 (CVAY736A2302) Sjögren's syndrome Indication Phase Phase 3 Patients 489 Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Arm 1: Experimental - ianalumab exposure level 1 Arm 2: Experimental - ianalumab exposure level 2 Arm 3: Placebo comparator Patients with active Sjogren's syndrome Primary 2026 Publication TBD ianalumab - BAFF-R inhibitor NCT05350072 NEPTUNUS-1 (CVAY736A2301) Sjögren's syndrome Phase 3 Indication Phase Patients 268 Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Publication Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Arm 1: Experimental - ianalumab Arm 2: Placebo comparator Patients with active Sjogren's syndrome Primary 2026 TBD □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 60

View entire presentation